Ultragenyx Pharmaceutical Inc. (RARE)

$43.69

+1.32

(+3.12%)▲

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Ultragenyx Pharmaceutical Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 98.05M → 127.39M (in $), with an average increase of 23.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -163.97M → -123.19M (in $), with an average increase of 10.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 41.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 292.8%

Performance

  • $42.48
    $44.40
    $43.69
    downward going graph

    2.77%

    Downside

    Day's Volatility :4.32%

    Upside

    1.6%

    downward going graph
  • $31.52
    $54.98
    $43.69
    downward going graph

    27.86%

    Downside

    52 Weeks Volatility :42.67%

    Upside

    20.53%

    downward going graph

Returns

PeriodUltragenyx Pharmaceutical Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-5.06%
-0.7%
0.0%
6 Months
32.41%
9.2%
0.0%
1 Year
-2.84%
3.5%
-1.3%
3 Years
-61.08%
12.3%
-22.1%

Highlights

Market Capitalization
3.5B
Book Value
$3.35
Earnings Per Share (EPS)
-8.25
PEG Ratio
-0.24
Wall Street Target Price
89.95
Profit Margin
-139.7%
Operating Margin TTM
-95.81%
Return On Assets TTM
-23.43%
Return On Equity TTM
-193.23%
Revenue TTM
434.2M
Revenue Per Share TTM
5.91
Quarterly Revenue Growth YOY
23.3%
Gross Profit TTM
-370.8M
EBITDA
-543.2M
Diluted Eps TTM
-8.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.45
EPS Estimate Next Year
-4.97
EPS Estimate Current Quarter
-1.62
EPS Estimate Next Quarter
-1.68

Analyst Recommendation

Buy
    88%Buy
    12%Hold
    0
    0%Sell
Based on 25 Wall street analysts offering stock ratings for Ultragenyx Pharmaceutical Inc.(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
22
23
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 105.88%

Current $43.69
Target $89.95

Company Financials

FY18Y/Y Change
Revenue
51.5M
↑ 1871.48%
Net Income
-197.6M
↓ 34.6%
Net Profit Margin
-383.75%
↑ 11183.59%
FY19Y/Y Change
Revenue
103.7M
↑ 101.41%
Net Income
-402.7M
↑ 103.8%
Net Profit Margin
-388.31%
↓ 4.56%
FY20Y/Y Change
Revenue
271.0M
↑ 161.32%
Net Income
-186.6M
↓ 53.67%
Net Profit Margin
-68.84%
↑ 319.47%
FY21Y/Y Change
Revenue
351.4M
↑ 29.66%
Net Income
-454.0M
↑ 143.36%
Net Profit Margin
-129.2%
↓ 60.36%
FY22Y/Y Change
Revenue
363.3M
↑ 3.39%
Net Income
-707.4M
↑ 55.81%
Net Profit Margin
-194.71%
↓ 65.51%
FY23Y/Y Change
Revenue
434.2M
↑ 19.52%
Net Income
-606.6M
↓ 14.25%
Net Profit Margin
-139.7%
↑ 55.01%
Q3 FY22Q/Q Change
Revenue
90.7M
↑ 1.52%
Net Income
-245.1M
↑ 54.97%
Net Profit Margin
-270.23%
↓ 93.2%
Q4 FY22Q/Q Change
Revenue
103.3M
↑ 13.94%
Net Income
-151.8M
↓ 38.05%
Net Profit Margin
-146.91%
↑ 123.32%
Q1 FY23Q/Q Change
Revenue
100.5M
↓ 2.76%
Net Income
-164.0M
↑ 7.99%
Net Profit Margin
-163.16%
↓ 16.25%
Q2 FY23Q/Q Change
Revenue
108.3M
↑ 7.77%
Net Income
-159.8M
↓ 2.53%
Net Profit Margin
-147.57%
↑ 15.59%
Q3 FY23Q/Q Change
Revenue
98.1M
↓ 9.47%
Net Income
-159.6M
↓ 0.11%
Net Profit Margin
-162.82%
↓ 15.25%
Q4 FY23Q/Q Change
Revenue
127.4M
↑ 29.92%
Net Income
-123.2M
↓ 22.84%
Net Profit Margin
-96.7%
↑ 66.12%
FY18Y/Y Change
Total Assets
719.6M
↑ 46.62%
Total Liabilities
110.7M
↑ 3.12%
FY19Y/Y Change
Total Assets
1.1B
↑ 57.8%
Total Liabilities
481.7M
↑ 335.37%
FY20Y/Y Change
Total Assets
1.8B
↑ 54.96%
Total Liabilities
605.2M
↑ 25.63%
FY21Y/Y Change
Total Assets
1.5B
↓ 13.48%
Total Liabilities
599.8M
↓ 0.88%
FY22Y/Y Change
Total Assets
1.5B
↑ 1.51%
Total Liabilities
1.2B
↑ 98.88%
FY23Y/Y Change
Total Assets
1.5B
↓ 3.52%
Total Liabilities
1.2B
↑ 1.9%
Q3 FY22Q/Q Change
Total Assets
1.6B
↑ 22.55%
Total Liabilities
1.1B
↑ 78.92%
Q4 FY22Q/Q Change
Total Assets
1.5B
↓ 4.51%
Total Liabilities
1.2B
↑ 3.77%
Q1 FY23Q/Q Change
Total Assets
1.4B
↓ 10.49%
Total Liabilities
1.2B
↓ 2.52%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 5.21%
Total Liabilities
1.2B
↑ 1.66%
Q3 FY23Q/Q Change
Total Assets
1.2B
↓ 5.58%
Total Liabilities
1.2B
↑ 2.04%
Q4 FY23Q/Q Change
Total Assets
1.5B
↑ 20.42%
Total Liabilities
1.2B
↑ 0.76%
FY18Y/Y Change
Operating Cash Flow
-290.6M
↑ 14.47%
Investing Cash Flow
-33.3M
↓ 160.08%
Financing Cash Flow
336.9M
↑ 147.2%
FY19Y/Y Change
Operating Cash Flow
-345.4M
↑ 18.87%
Investing Cash Flow
-13.0M
↓ 60.88%
Financing Cash Flow
679.3M
↑ 101.66%
FY20Y/Y Change
Operating Cash Flow
-132.2M
↓ 61.72%
Investing Cash Flow
-179.1M
↑ 1273.73%
Financing Cash Flow
600.3M
↓ 11.63%
FY21Y/Y Change
Operating Cash Flow
-338.7M
↑ 156.16%
Investing Cash Flow
-195.4M
↑ 9.07%
Financing Cash Flow
118.6M
↓ 80.25%
FY22Y/Y Change
Operating Cash Flow
-380.5M
↑ 12.33%
Investing Cash Flow
-291.7M
↑ 49.28%
Financing Cash Flow
501.2M
↑ 322.77%
Q3 FY22Q/Q Change
Operating Cash Flow
-95.3M
↑ 23.41%
Investing Cash Flow
-161.9M
↓ 304.45%
Financing Cash Flow
491.9M
↑ 8326.88%
Q4 FY22Q/Q Change
Operating Cash Flow
-90.3M
↓ 5.25%
Investing Cash Flow
-171.6M
↑ 6.02%
Financing Cash Flow
1.9M
↓ 99.62%
Q1 FY23Q/Q Change
Operating Cash Flow
-156.9M
↑ 73.64%
Investing Cash Flow
111.3M
↓ 164.86%
Financing Cash Flow
-722.0K
↓ 138.36%

Technicals Summary

Sell

Neutral

Buy

Ultragenyx Pharmaceutical Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
-7.59%
32.41%
-2.84%
-61.08%
-35.17%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
NA
NA
-0.24
-6.45
-1.93
-0.23
NA
3.35
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Buy
$3.6B
-35.17%
NA
-139.7%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Vanguard Group Inc

    10.53%

  • RTW INVESTMENTS, LLC

    8.36%

  • BlackRock Inc

    6.36%

  • Wellington Management Company LLP

    5.36%

  • Sands Capital Management, LLC

    5.00%

  • T. Rowe Price Associates, Inc.

    4.19%

Corporate Announcements

  • Ultragenyx Pharmaceutical Inc. Earnings

    Ultragenyx Pharmaceutical Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d

Organization
Ultragenyx Pharmaceutical Inc.
Employees
1276
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs